Background We have previously reported an age-related impairment in the serum antibody
response to pandemic (p) 2009 H1N1, measured by hemagglutination inhibition assay and …

Background. The world is facing a novel H1N1 influenza pandemic. A pandemic scare with
a similar influenza virus in 1976 resulted in the vaccination of nearly 45 million persons. We …

The immunogenicity of current influenza virus vaccines is assessed by measuring an
increase of influenza virus-specific antibodies in a hemagglutination inhibition assay. This …

Compared to intramuscular vaccines, nasally administered vaccines have the advantage of
inducing local mucosal immune responses that may block infection and interrupt …

The majority of patients with pandemic influenza H1N1 2009 had mild illness, but some,
including those with no risk factors for severe disease, may succumb to this infection …

Introduction A Proteosome-adjuvanted trivalent inactivated influenza vaccine (P-TIV)
administered intra-nasally was shown to be safe, well tolerated and immunogenic in both …

Background. Although pregnant women are at increased risk of severe illness following
influenza infection, there is relatively little information on the immunogenicity of influenza …

While live attenuated influenza vaccines (LAIVs) have been shown to be efficacious and
have been licensed for human use, the surface glycoproteins hemagglutinin (HA) and …

The influenza virus neuraminidase (NA) is primarily involved in the release of progeny
viruses from infected cells—a critical role for virus replication. Compared to the immuno …

To identify immunological predictors of resistance to influenza A infection and illness, the
immunological status of live and inactivated virus vaccines subsequently challenged with …